BID TerminalOpen the Terminal

Research library · Healthcare

Healthcare: the moats, the numbers, the verdicts.

17 companies covered. Every report re-run after the latest earnings.

AbbVie Inc. ABBV

Skyrizi and Rinvoq together did $8.03B last quarter, growing 15%. Humira did $756M.

Back of Napkin

Abbott Laboratories ABT

Five days ago it agreed to pay roughly $670M to settle infant formula litigation, with about 1,700 lawsuits still outstanding.

Back of Napkin

Bristol-Myers Squibb Company BMY

Bristol Myers now calls $7.6B of its $13.0B quarterly revenue the Growth Portfolio, and that half grew 15% last quarter.

Back of Napkin

ClearPoint Neuro, Inc. CLPT

ClearPoint Neuro sells $42.3M of trailing revenue for about twelve times sales while losing more each quarter than the quarter before.

Back of Napkin

Halozyme Therapeutics, Inc. HALO

Halozyme is a royalty engine on subcutaneous biologics, throwing off ≈$573M EBITDA on $1.4B revenue with 78% gross margins, but the stock sits at 23x trailing earnings because the

Back of Napkin

Hims & Hers Health, Inc. HIMS

Two quarters ago Hims & Hers grew 3.8% and earned money. Last quarter it grew 38.2% and lost $97.2M at the operating line.

Back of Napkin

IDEXX Laboratories, Inc. IDXX

IDEXX is a razor-and-blade veterinary-diagnostics franchise earning a 40% return on capital, where recurring consumables and lab services compounded near double-digits straight thr

Back of Napkin

IQVIA Holdings Inc. IQV

IQVIA's contracted backlog reached $34.2B and its book-to-bill ratio hit 1.22, meaning it signed $1.22 of new work for every dollar it delivered.

Back of Napkin

Eli Lilly and Company LLY

Two drugs now produce 65% of Eli Lilly's revenue. Mounjaro alone grew 91% to $9.94B in a single quarter.

Back of Napkin

Mettler-Toledo International Inc. MTD

Mettler-Toledo is the highest-return business in the lab-and-industrial-instruments group, earning a 36% return on invested capital while the stock has fallen 24% from its 52-week

Back of Napkin

Novo Nordisk A/S NVO

Eli Lilly's two obesity and diabetes medicines produced about $14.8B of revenue last quarter, more than Novo Nordisk's entire company.

Moat Dive · Back of Napkin

Pfizer Inc. PFE

Pfizer has written off $8.7B of acquired drug programmes in two of the last three quarters.

Back of Napkin

Royalty Pharma plc RPRX

Royalty Pharma collected $773M of cash last quarter and reported $17.9M of net income.

Back of Napkin

Universal Health Services, Inc. UHS

Universal Health Services sits at 6.3x trailing earnings and 6.3x forward, with the stock down 41% from its 52-week high while FY25 EPS grew 37% and operating income jumped 19%.

Back of Napkin

UnitedHealth Group Incorporated UNH

UnitedHealth's operating income collapsed to $380M in the December quarter, from $5.15B a year earlier, and has since recovered to $7.99B.

Back of Napkin

West Pharmaceutical Services, Inc. WST

West Pharmaceutical Services makes the rubber stoppers, plungers, and seals that sit between every injectable drug and the human bloodstream, a single-source qualified component fo

Back of Napkin

Zoetis Inc. ZTS

Zoetis has lost half its market value, from $157.21 to $77.17, while reported earnings per share went from $1.63 to $1.65.

Back of Napkin